Back to Alzheimers Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03814603

NCT03814603
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You are a man or woman between 60 and 75 years old with normal memory and thinking abilities.
  • Your neurological (brain and nervous system) and mental health check-ups are within normal ranges, with no signs of cognitive decline.
  • A family member or close companion (preferably someone you live or sleep with) is available to answer a few questions by phone or in person to confirm information you provide.
  • You identify yourself as African-American Black or non-Hispanic white.
  • You are willing and able to sign the Alzheimer's Disease Center consent form.

Who may not be able to join:

  • You have a history of brain tumors, significant brain injury, seizures, hydrocephalus (fluid on the brain), intellectual disability, Parkinson's disease, or other serious brain or nervous system conditions.
  • You have a significant history of alcohol misuse (based on a short questionnaire) or drug abuse.
  • You have a history of serious mental health conditions such as schizophrenia, bipolar disorder, or PTSD.
  • You have had an active episode of depression or anxiety within the last two years (a long-term history of depression or anxiety that is currently stable may be acceptable — confirm with trial site).
  • You score above 6 on a short depression screening questionnaire called the Geriatric Depression Scale.
  • You require insulin to manage diabetes.
  • You have significant heart, lung, hormonal, or blood-related health conditions, based on the doctor leading the trial's judgment.
  • You have a physical limitation severe enough to affect the reliability of memory and thinking tests.
  • You have any implanted medical devices (such as a pacemaker or surgical clips) that are not safe for MRI scans.
  • You currently take certain medications that can affect memory, thinking, or deep sleep — including narcotic painkillers, some Parkinson's medications, antidepressants of specific types, or a range of other listed medications (confirm with trial site for the full list).
  • You have a close blood relative (parent or sibling) who developed dementia before age 60.
  • You regularly sleep fewer than 5 hours or more than 10 hours per day.
  • You have been diagnosed with obstructive sleep apnea meeting specific severity criteria (confirm with trial site).
  • You identify as Caribbean Black (US-born or Caribbean-born) or African-born Black.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
NYU Langone Health
Registry
clinicaltrials_gov
Start date
21 November 2018
Est. completion
31 May 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Association between Percentage of African Ancestry (%AF) and Slow Wave Sleep (SWS) duration and activity (SWA).; Examine association between SWS duration and poor SWA with longitudinal change in amyloid burden.; Examine the association between race, SWS duration and poor SWA and cognition using both standardized and sleep-dependent cognitive tests at baseline and follow-up.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov